Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aviral Singh

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Oncotarget|April 24, 2018
Results and adverse events of personalized peptide receptor radionuclide therapy with <sup>90</sup>Yttrium and <sup>177</sup>Lutetium in 1048 patients with neuroendocrine neoplasmsRichard P Baum, Harshad R Kulkarni, Aviral Singh, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 8, 2016
<sup>64</sup>Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human StudiesBernhard Grubmüller, Richard P Baum, Enza Capasso, et al.
Seminars in Nuclear Medicine|September 1, 2019
From Bench to Bedside-The Bad Berka Experience With First-in-Human StudiesJingjing Zhang, Aviral Singh, Harshad R Kulkarni, et al.
EJNMMI Research|July 27, 2019
Preclinical investigations and first-in-human application of <sup>152</sup>Tb-PSMA-617 for PET/CT imaging of prostate cancerCristina Müller, Aviral Singh, Christoph A Umbricht, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 28, 2018
PRRT genomic signature in blood for prediction of <sup>177</sup>Lu-octreotate efficacyLisa Bodei, Mark S Kidd, Aviral Singh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2021
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using <sup>177</sup>Lu-FAP-2286: First-in-Humans ResultsRichard P Baum, Christiane Schuchardt, Aviral Singh, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 16, 2019
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETestLisa Bodei, Mark S Kidd, Aviral Singh, et al.
Dalton Transactions (Cambridge, England : 2003)|August 22, 2017
Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with <sup>152</sup>Tb-DOTATOCRichard P Baum, Aviral Singh, Martina Benešová, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 2021
First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOCRichard P Baum, Aviral Singh, Harshad R Kulkarni, et al.
The Lancet. Oncology|January 13, 2024
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective studyMike M Sathekge, Ismaheel O Lawal, Chandrasekhar Bal, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Oncotarget|April 24, 2018
Results and adverse events of personalized peptide receptor radionuclide therapy with <sup>90</sup>Yttrium and <sup>177</sup>Lutetium in 1048 patients with neuroendocrine neoplasmsRichard P Baum, Harshad R Kulkarni, Aviral Singh, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 8, 2016
<sup>64</sup>Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human StudiesBernhard Grubmüller, Richard P Baum, Enza Capasso, et al.
Seminars in Nuclear Medicine|September 1, 2019
From Bench to Bedside-The Bad Berka Experience With First-in-Human StudiesJingjing Zhang, Aviral Singh, Harshad R Kulkarni, et al.
EJNMMI Research|July 27, 2019
Preclinical investigations and first-in-human application of <sup>152</sup>Tb-PSMA-617 for PET/CT imaging of prostate cancerCristina Müller, Aviral Singh, Christoph A Umbricht, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 28, 2018
PRRT genomic signature in blood for prediction of <sup>177</sup>Lu-octreotate efficacyLisa Bodei, Mark S Kidd, Aviral Singh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2021
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using <sup>177</sup>Lu-FAP-2286: First-in-Humans ResultsRichard P Baum, Christiane Schuchardt, Aviral Singh, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 16, 2019
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETestLisa Bodei, Mark S Kidd, Aviral Singh, et al.
Dalton Transactions (Cambridge, England : 2003)|August 22, 2017
Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with <sup>152</sup>Tb-DOTATOCRichard P Baum, Aviral Singh, Martina Benešová, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 2021
First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOCRichard P Baum, Aviral Singh, Harshad R Kulkarni, et al.
The Lancet. Oncology|January 13, 2024
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective studyMike M Sathekge, Ismaheel O Lawal, Chandrasekhar Bal, et al.
Pageof 6